Company Overview and News

 
Who are the Top 3 Biotech Takeover Targets?

3h biospace
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right. The biggest deals have been Sanofi’s acquisition of Bioverativ for about $11.6 billion and Ablynx for $4.8 billion, both in January. Also in January, Celgene Corporation bought Juno Therapeutics for about $9 billion, then shortly afterwards Celgene bought Impact Biomedicines for $1.

1
Lucky Seven: Exelixis Bounces Back, Global Blood Therapeutics Bleeds

2018-05-19 seekingalpha
As predicted, shares in Global Blood Therapeutics bled late into last week. We will almost certainly hold into data on conviction based on reasoning and odds.

 
GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European Hematology Association (EHA) Congress

2018-05-17 globenewswire
SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that data supporting its voxelotor program in sickle cell disease (SCD) will be presented during the 23rd European Hematology Association (EHA) Congress in Stockholm, taking place June 14-17, 2018. A total of five abstracts have been accepted for poster presentation including 24-week data on patients treated with the 900 mg dose of voxelotor in Part B of the HOPE-KIDS 1 Study (GBT440-007), a Phase 2a open-label study in adolescents ages 12 to 17.

2
Lucky Seven: Achaogen Likely To Bounce Back

2018-05-14 seekingalpha
We have reasons to believe Achaogen will bounce back and resume its upward momentum. In anticipation of this, Achaogen will replace Omeros in the Lucky Seven portfolio.

1
2 Small Biotechs For The Rest Of 2018

2018-05-11 seekingalpha
Our last piece this trading week is on a couple of biotech companies that are well positioned to do well for the rest of 2018.

 
Rounds Report: Global Blood Therapeutics Rallied While Improving FDA Policies To Help Nektar

2018-05-10 seekingalpha
Despite that the bioscience market experienced a weak trading day, notable movers topped our list. Global Blood Therapeutics broke the trend and experienced a trading reversal.

2
Lucky Seven: Omeros Moves, Array Biopharma May Be Next

2018-05-08 seekingalpha
Global Blood Therapeutics posts 1Q earnings and provides update. Given the likelihood of a significant catalyst within a few weeks, we are moving its position to reflect greater risk.

 
GBT / Global Blood Therapeutics, Inc. FORM 8-K (Current Report)

2018-05-07 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT

2
GBT / Global Blood Therapeutics, Inc. 10-Q (Quarterly Report)

2018-05-07 sec.gov
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
GBT Announces New Employment Inducement Grants

2018-05-04 globenewswire
SOUTH SAN FRANCISCO, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on May 1, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 14,250 shares of the Company’s common stock with a per share exercise price of $45.20, the closing trading price on the grant date, and restricted stock units for an aggregate of 9,400 shares of the Company’s common stock.

1
Global Blood Therapeutics: The Anatomy Of A Senseless Drop

2018-04-30 seekingalpha
A raise, downgrade, and headwind saw Global Blood Therapeutics' share price plummeting back down to earth.

3
GBT / Global Blood Therapeutics, Inc. DEF 14A

2018-04-27 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION

3
GBT / Global Blood Therapeutics, Inc. DEFA14A

2018-04-27 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

5
GBT / Global Blood Therapeutics, Inc. DEFA14A

2018-04-27 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

GBT: Global Blood Therapeutics Analysis and Research Report

2018-03-26 - Asif

Overview Global Blood Therapeutics is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. The company's lead product candidate is voxelotor (previously known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believe inhibits hemoglobin polymerization in sickle cell disease, or SCD. Global Blood Therapeutics is currently evaluating voxelotor in SCD in a Phase 3 clinical trial in adult and adolescent patients with SCD. In addition, Global Blood Therapeutics is evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase 2a clinical trial of adolescent and pediatric patients with SCD, and in July 2017 the company announced that Global Blood Therapeutics has expanded this open-label trial to include a new single-dose cohort in children aged 6-11. In December 2015, the Food and Dr...

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 37890U108